Giving the entire issue a ‘generic drugmakers versus innovators’ and ‘affordable drugs versus expensive drugs’ twist, Malvinder Singh, managing director, Ranbaxy, on Friday reiterated the accusation against the unnamed big pharma multinational company (MNC) of deliberately trying to destabilise the Daiichi Sankyo-Ranbaxy deal, which he said could harm the business interests of the MNC in question.
Sniffing a larger conspiracy by a big pharma MNC, Singh said, “clearly, there is a large MNC, which is trying to scuttle the deal, whose sales will greatly suffer if the deal goes through. I have been getting many phone calls pointing fingers towards the same company”.
According to Ranbaxy, the issues related to the company, which are being raised now are old and have no new element to them. The investigations have been on for a few years now, however the very ‘timing’, (days following June 11 when the Daiichi-Ranbaxy deal was announced) when the issues are raked up makes the company even more suspicious of a larger ploy being hatched by the parties who are likely to suffer if the deal goes through.
Asked if Ranbaxy will talk to other global generic drug makers to address the issue, Singh said, “We will explore all possibilities.” According to Ranbaxy, the deal between the Indian pharma major and Japanese drugmaker sets a new business model in the industry that has the potential to change the complexion of the global pharma business.